ArticleCancer biotherapy & radiopharmaceuticals2015

One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.

Hossein Jadvar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.